Pharmacielo Stock Net Income
PCLO Stock | CAD 0.09 0.01 13.33% |
Pharmacielo fundamentals help investors to digest information that contributes to Pharmacielo's financial success or failures. It also enables traders to predict the movement of Pharmacielo Stock. The fundamental analysis module provides a way to measure Pharmacielo's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmacielo stock.
Last Reported | Projected for Next Year | ||
Net Loss | -16.3 M | -17.1 M | |
Net Loss | -24 M | -25.2 M | |
Net Loss | -16.3 M | -17.1 M | |
Net Loss | (0.10) | (0.11) | |
Net Income Per E B T | 0.99 | 0.82 |
Pharmacielo | Net Income |
Pharmacielo Company Net Income Analysis
Pharmacielo's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pharmacielo Net Income | (16.3 M) |
Most of Pharmacielo's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmacielo is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pharmacielo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pharmacielo is extremely important. It helps to project a fair market value of Pharmacielo Stock properly, considering its historical fundamentals such as Net Income. Since Pharmacielo's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharmacielo's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharmacielo's interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Pharmacielo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pharmacielo reported net income of (16.3 Million). This is 104.78% lower than that of the Pharmaceuticals sector and 95.77% lower than that of the Health Care industry. The net income for all Canada stocks is 102.85% higher than that of the company.
Pharmacielo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmacielo's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmacielo could also be used in its relative valuation, which is a method of valuing Pharmacielo by comparing valuation metrics of similar companies.Pharmacielo is currently under evaluation in net income category among its peers.
Pharmacielo Fundamentals
Return On Equity | -30.13 | ||||
Return On Asset | -0.2 | ||||
Operating Margin | (2.12) % | ||||
Current Valuation | 32.83 M | ||||
Shares Outstanding | 169.74 M | ||||
Shares Owned By Insiders | 8.43 % | ||||
Shares Owned By Institutions | 4.58 % | ||||
Number Of Shares Shorted | 28.63 K | ||||
Price To Book | 9.48 X | ||||
Price To Sales | 7.86 X | ||||
Revenue | 1.54 M | ||||
Gross Profit | (4.17 M) | ||||
EBITDA | (7.56 M) | ||||
Net Income | (16.3 M) | ||||
Cash And Equivalents | 33.46 M | ||||
Cash Per Share | 0.34 X | ||||
Total Debt | 15.71 M | ||||
Debt To Equity | 2.70 % | ||||
Current Ratio | 7.36 X | ||||
Book Value Per Share | (0.03) X | ||||
Cash Flow From Operations | (5.15 M) | ||||
Short Ratio | 0.11 X | ||||
Earnings Per Share | (0.08) X | ||||
Target Price | 2.5 | ||||
Beta | 2.39 | ||||
Market Capitalization | 12.73 M | ||||
Total Asset | 22.29 M | ||||
Retained Earnings | (198.71 M) | ||||
Working Capital | (18.09 M) | ||||
Net Asset | 22.29 M |
About Pharmacielo Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacielo's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacielo using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacielo based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pharmacielo Stock Analysis
When running Pharmacielo's price analysis, check to measure Pharmacielo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacielo is operating at the current time. Most of Pharmacielo's value examination focuses on studying past and present price action to predict the probability of Pharmacielo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacielo's price. Additionally, you may evaluate how the addition of Pharmacielo to your portfolios can decrease your overall portfolio volatility.